September 9, 2017

Mass. Senate Bill Calls on FDA to Clarify Inducement of Cancer Trial Subjects

A Massachusetts Senate bill calls on the FDA to clarify the “difference between what is considered ‘inducement’ for a patient to participate in a clinical trial and the reimbursement of expenses for participating in a cancer clinical trial.”


You must be a subscriber to access this information. If you are a subscriber, please login. Not Yet A Subscriber? Click here to register for a free trial or contact Client Services at 800-677-3789 to activate your subscription.

Feedback Form
Leads to Insight